NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05923684
Collaborator
National Cancer Institute (NCI) (NIH)
30
1
24

Study Details

Study Description

Brief Summary

In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigators will report the top five sentences from each consultation across key content areas (cancer prognosis, life expectancy, erectile dysfunction, urinary incontinence, and irritative urinary symptoms) to both patients and physicians within 2 weeks of the consultation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: NLP-based Feedback
N/A

Detailed Description

The primary research procedures are:
  1. Audio recording and transcribing treatment counseling discussions for 20 men with newly diagnosed clinically localized prostate cancers and utilize NLP to extract key content using the system described above.

  2. Reports including the top five sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within 2 weeks after each case.

  3. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback.

  4. For physicians, the investigators will assess baseline quality of risk communication, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.

  5. Within 2 weeks of receiving the NLP-based feedback, the investigators will conduct a 30-minute semi-structured interview with patients to obtain their opinions on the utility and ideal implementation strategy for the NLP-based feedback.

  6. At the conclusion of the pilot trial, the investigators will conduct 30-minute semi-structured interview with counseling physicians to obtain their opinions on the utility and ideal implementation strategy for the NLP-based feedback.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Natural Language Processing-Based Feedback to Improve Physician Risk Communication and Informed Shared Decision Making in Men With Clinically Localized Prostate Cancer
Anticipated Study Start Date :
Jul 15, 2023
Anticipated Primary Completion Date :
Jul 15, 2024
Anticipated Study Completion Date :
Jul 15, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: NLP Intervention Experimental Arm

20 men with newly diagnosed clinically localized prostate cancers and utilize NLP to extract key content using the top five sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within 2 weeks after each case.

Behavioral: NLP-based Feedback
Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.

Outcome Measures

Primary Outcome Measures

  1. Change in Decisional Conflict Scale Scores before and after intervention (patient-level outcome) [Measured directly after treatment consultation and after NLP-based feedback given to patients within 2 weeks of consultation]

    The investigators will employ the validated Decisional Conflict Scale (DCS), to estimate uncertainty associated with treatment choice. Effect sizes of 0.3 to 0.4 are considered meaningful. Variability (standard deviation) in DCS scores before and after receiving NLP-based feedback will be assessed and used in planning a larger trial.

  2. Change in risk perception before and after intervention (patient-level outcome) [Measured directly after treatment consultation and after NLP -based feedback given to patients within 2 weeks of consultation]

    The investigators will evaluate concordance of cancer risk perception with actual cancer risk at the patient level before and after the intervention. Cancer risk perception will be assessed by multiple-choice questions. Concordance of patient answers with actual cancer risk as estimated by outcomes of the SPCG-4 randomized trial comparing surgery versus watchful waiting at the patient's PCCI-predicted life expectancy will be assessed as a binary outcome. Risk perception will be assessed before and after their consultation. Variability (standard deviation) in risk perception scores before and after receiving NLP-based feedback will be assessed and used in planning a larger trial.

  3. Physician attitudes regarding integration of NLP-based information (physician-level outcome) [Interviews will be conducted within 2 weeks of the intervention.]

    30-minute semi-structured interviews with counseling physicians will be conducted within 2 weeks of the intervention to obtain their opinions on the utility and ideal implementation strategy for the NLP-based feedback.

  4. Difference between reported risk of side effects and prognosis with gold standard (physician-level outcome) [Data will be captured during the treatment consultation-for the duration of the study up to 1 year]

    The difference in reported risk estimates given by physicians during the consultation as compared with the gold standards for these risks (i.e. for side effects, estimates from the CAESAR study; for cancer risk with and without treatment, risks of cancer mortality in the WW group of SPCG-4 trial at the patient's life expectancy as determined by the prostate cancer comorbidity index). Variability (standard deviation) in accuracy of estimates will be assessed and used in planning a larger trial. Accuracy of estimates for the interventional period will be compared with physician-specific historical references from a previously conducted trial using the standard of care (i.e. no NLP-based intervention).

  5. Quality of composite physician risk communication score in treatment consultation (physician-level outcome) [Data will be captured during the treatment consultation, for duration of the study up to 1 year]

    Quality of risk communication scores will be calculated by qualitatively analyzing treatment consultation transcripts to assess the highest quality of communication used to transmit information regarding all key tradeoffs (cancer prognosis, life expectancy, erectile dysfunction, urinary incontinence, and irritative urinary symptoms). The quality of risk communication scale ranges from 0 to 5 for each outcome, with 0 representing the lowest score and 5 representing the highest score (Daskivich et al, J Urol 2022; Naser-Tavakolian et al, J Urol 2022). Scores for all key tradeoffs will be averaged to yield a composite quality of risk communication score. Variability (standard deviation) in quality scores will be assessed and used in planning a larger trial.

  6. Patient attitudes regarding integration of NLP-based information [within 4 weeks of patients using NLP system.]

    30-minute semi-structured interviews with patients will be conducted at the conclusion of the study period to obtain their opinions on the utility and ideal implementation strategy for the NLP-based feedback

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Men undergoing initial treatment consultation for clinically localized prostate cancer;

  2. Men with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy.

  3. Cedars-Sinai patient.

  4. Ability to read and write in English.

Exclusion Criteria:
  1. Under 18 years of age;

  2. Subjects with difficulty communicating or dementia;

  3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English;

  4. Men with locally advanced or metastatic prostate cancer;

  5. Men who have already been treated for clinically localized prostate cancer

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cedars-Sinai Medical Center
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Timothy Daskivich, Cedars-Sinai Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Timothy J. Daskivich, Assistant Professor, Department of Urology, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT05923684
Other Study ID Numbers:
  • STUDY00002590
  • K08CA230155
First Posted:
Jun 28, 2023
Last Update Posted:
Jun 28, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Timothy J. Daskivich, Assistant Professor, Department of Urology, Cedars-Sinai Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2023